Teva falls on disappointing sales forecast; Akcea and PTC take two drugs to Latin America
→ Teva $TEVA upped its profit outlook for the year today, but nevertheless saw its share price drop by about 5% as analysts highlighted the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
